RecruitingNot ApplicableNCT06543940

Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane

Pharmacokinetics of Vancomycin in Patients Receiving Continuous Veno-Venous Hemodiafiltration (CVVHDF) with the Absorptive OXiris Membrane

Sponsor

Mahidol University

Enrollment

8 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

AKI - Acute Kidney Injury

Summary

This study is a general pharmacokinetic investigation of vancomycin in patients receiving continuous veno-venous hemodiafiltration (CRRT) with the oXiris membrane. This membrane offers the added benefit of absorbing inflammatory cytokines. In vitro studies show that vancomycin is reduced by around 20 percent in patients using the AN69ST membrane, which is part of the oXiris membrane's structure. However, there is currently a lack of in vivo studies demonstrating the impact of the oXiris membrane on vancomycin levels. Therefore, the hypothesis of this study is that vancomycin is also reduced by absorption in the oXiris membrane. This study measures the levels of vancomycin in these patients to determine the pharmacokinetic parameters.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Patients aged more than 18 years.
Admitted to the intensive care unit of Ramathibodi Hospital.
Under continuous renal replacement therapy (CRRT) with CVVHDF using oXiris filter.
Received vancomycin at least once after starting CRRT with CVVHDF using oXiris filter.
who have signed the informed consent document.

Exclusion Criteria8

Patients with a history of vancomycin allergy.
Patients expected to die within 24 hours after inclusion in study.
Patients with circuit clotting occurring more than 2 hours during the blood draw period.
Patients treated with extracorporeal membrane oxygenation (ECMO).
Patients with a history of kidney transplantation.
Pregnant or breastfeeding women.
Patients who have decided to receive palliative care.
Patients on hemodialysis or peritoneal dialysis.